GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Gross Profit

Advanced Oncotherapy (FRA:R3I1) Gross Profit : €0.00 Mil (TTM As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Gross Profit?

Advanced Oncotherapy's gross profit for the six months ended in Jun. 2022 was €0.00 Mil. Advanced Oncotherapy's gross profit for the trailing twelve months (TTM) ended in Jun. 2022 was €0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Advanced Oncotherapy's gross profit for the six months ended in Jun. 2022 was €0.00 Mil. Advanced Oncotherapy's Revenue for the six months ended in Jun. 2022 was €0.00 Mil. Therefore, Advanced Oncotherapy's Gross Margin % for the quarter that ended in Jun. 2022 was N/A%.

Advanced Oncotherapy had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage


Advanced Oncotherapy Gross Profit Historical Data

The historical data trend for Advanced Oncotherapy's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Gross Profit Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -2.12 - - -

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Advanced Oncotherapy's Gross Profit

For the Medical Devices subindustry, Advanced Oncotherapy's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Gross Profit distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Gross Profit falls into.



Advanced Oncotherapy Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Advanced Oncotherapy's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Advanced Oncotherapy's Gross Profit for the quarter that ended in Jun. 2022 is calculated as

Gross Profit (Q: Jun. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Advanced Oncotherapy's Gross Margin % for the quarter that ended in Jun. 2022 is calculated as

Gross Margin % (Q: Jun. 2022 )=Gross Profit (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Advanced Oncotherapy  (FRA:R3I1) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Advanced Oncotherapy had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage


Advanced Oncotherapy Gross Profit Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy (FRA:R3I1) Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines